Researcher.Life Logo

American Journal of Cardiovascular Drugs : Impact Factor & More

eISSN: 1179-187XpISSN: 1175-3277

Key Metrics

CiteScore
5.9
Eigenfactor
0.001 - 0.005
H-Index
57
Impact Factor
< 5
SJR
Q2Pharmacology (medical)
SNIP
1.15
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on American Journal of Cardiovascular Drugs

American Journal of Cardiovascular Drugs Journal Specifications

Overview
Publisher ADIS INT LTD
Language English
Frequency Bi-monthly
General Details
LanguageEnglish
FrequencyBi-monthly
Publication Start Year2001
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in American Journal of Cardiovascular Drugs ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in American Journal of Cardiovascular Drugs

Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease: A Network Meta-analysis.
  • 1 Mar 2026
  • American journal of cardiovascular drugs : drugs, devices, and other interventions
Contemporary Antianginal Therapy.
  • 1 Mar 2026
  • American journal of cardiovascular drugs : drugs, devices, and other interventions
Beta-Blockers After Myocardial Infarction Without Reduced Ejection Fraction: A Meta-Analysis of Kaplan-Meier Reconstructed Individual Patient Data.
  • 19 Feb 2026
  • American journal of cardiovascular drugs : drugs, devices, and other interventions
Defining the Role of Intravenous Iron in The Treatment of Patients with Heart Failure with Reduced Ejection Fraction and Iron Deficiency.
  • 16 Feb 2026
  • American journal of cardiovascular drugs : drugs, devices, and other interventions
Cimlanod, a Second-Generation Nitroxyl Donor, in Heart Failure with Reduced Ejection Fraction: A Meta-Analysis of Hemodynamic Efficacy and Safety Profile.
  • 13 Feb 2026
  • American journal of cardiovascular drugs : drugs, devices, and other interventions
Targeting Factor XI for Safer Anticoagulation: Emerging Data and Future Directions.
  • 25 Jan 2026
  • American journal of cardiovascular drugs : drugs, devices, and other interventions
Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease: A Network Meta-analysis.
  • 1 Mar 2026
  • American journal of cardiovascular drugs : drugs, devices, and other interventions
Contemporary Antianginal Therapy.
  • 1 Mar 2026
  • American journal of cardiovascular drugs : drugs, devices, and other interventions
Beta-Blockers After Myocardial Infarction Without Reduced Ejection Fraction: A Meta-Analysis of Kaplan-Meier Reconstructed Individual Patient Data.
  • 19 Feb 2026
  • American journal of cardiovascular drugs : drugs, devices, and other interventions
Defining the Role of Intravenous Iron in The Treatment of Patients with Heart Failure with Reduced Ejection Fraction and Iron Deficiency.
  • 16 Feb 2026
  • American journal of cardiovascular drugs : drugs, devices, and other interventions
Cimlanod, a Second-Generation Nitroxyl Donor, in Heart Failure with Reduced Ejection Fraction: A Meta-Analysis of Hemodynamic Efficacy and Safety Profile.
  • 13 Feb 2026
  • American journal of cardiovascular drugs : drugs, devices, and other interventions
Targeting Factor XI for Safer Anticoagulation: Emerging Data and Future Directions.
  • 25 Jan 2026
  • American journal of cardiovascular drugs : drugs, devices, and other interventions

FAQs on American Journal of Cardiovascular Drugs